Terazosin hydrochloride - Generic Drug Details

What are the generic drug sources for terazosin hydrochloride and what is the scope of patent protection?

Terazosin hydrochloride is the generic ingredient in three branded drugs marketed by Abbott, Ajanta Pharma Ltd, Apnar Pharma Lp, Bionpharma, Heritage Pharma Avet, Hikma, Jubilant Cadista, Pharmobedient, Ranbaxy Labs Ltd, Novitium Pharma, Chartwell Rx, Ivax Sub Teva Pharms, Sandoz, and Teva, and is included in sixteen NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for terazosin hydrochloride. Twenty suppliers are listed for this compound.

Summary for terazosin hydrochloride

US Patents:	2
Tradenames:	3
Applicants:	14
NDAs:	16
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	20
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	29
Patent Applications:	2,169
What excipients (inactive ingredients) are in terazosin hydrochloride?	terazosin hydrochloride excipients list
DailyMed Link:	terazosin hydrochloride at DailyMed

Recent Clinical Trials for terazosin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nandakumar Narayanan	PHASE1
University of Iowa	EARLY_PHASE1
Michael J. Fox Foundation for Parkinson's Research	PHASE3

See all terazosin hydrochloride clinical trials

Pharmacology for terazosin hydrochloride

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for terazosin hydrochloride

G04CA	Alpha-adrenoreceptor antagonists
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for terazosin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	TABLET;ORAL	074657-002	Apr 28, 2000		DISCN	No	No
Sandoz	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	TABLET;ORAL	074315-004	Dec 31, 1998		DISCN	No	No
Abbott	HYTRIN	terazosin hydrochloride	CAPSULE;ORAL	020347-004	Dec 14, 1994		DISCN	Yes	No
Bionpharma	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	075667-002	Jul 28, 2000	AB	RX	No	No
Ajanta Pharma Ltd	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	219482-004	May 12, 2025	AB	RX	No	No
Ivax Sub Teva Pharms	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	TABLET;ORAL	074530-003	Apr 21, 2000		DISCN	No	No

Expired US Patents for terazosin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-004	Aug 7, 1987	5,294,615
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-002	Aug 7, 1987	4,026,894
Abbott	HYTRIN	terazosin hydrochloride	CAPSULE;ORAL	020347-002	Dec 14, 1994	5,412,095
Abbott	HYTRIN	terazosin hydrochloride	CAPSULE;ORAL	020347-003	Dec 14, 1994	5,412,095
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-001	Aug 7, 1987	4,251,532
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-004	Aug 7, 1987	4,112,097

Market Dynamics and Financial Trajectory for Terazosin Hydrochloride

Last updated: February 19, 2026

Summary:
Terazosin Hydrochloride is a selective alpha-1 adrenergic receptor blocker primarily prescribed for benign prostatic hyperplasia (BPH) and hypertension. It has been marketed since the late 1980s, with a stable presence in the U.S. and global markets. The drug’s sales are influenced by generic entry, competition from other alpha-blockers, and evolving treatment guidelines. While its patent expired in the early 2000s, it remains clinically relevant due to established efficacy and low cost, supporting ongoing demand. The financial trajectory is shaped by generic sales, market penetration, and healthcare policies affecting drug reimbursement and prescribing habits.

---

What Are the Key Market Drivers for Terazosin Hydrochloride?

1. Generic Competition and Price Trends

Patents expired around 2003, allowing generic versions to enter markets globally. Generic versions significantly reduce price points, leading to increased accessibility and volume-based growth. As of 2022, generic Terazosin accounts for approximately 85% of U.S. prescriptions for alpha-1 blockers treating BPH.

2. Prescribing Patterns and Clinical Preference

Physicians favor established, low-cost options like Terazosin for BPH, especially in healthcare systems emphasizing cost-effectiveness. However, newer agents such as Tamsulosin have gained preference due to fewer side effects, impacting market share.

3. Regulatory and Healthcare Policy Environment

Insurance coverage and formulary inclusion significantly influence sales. Reimbursement policies favor generic drugs, supporting volume growth. Regulatory approvals in emerging markets, particularly in Asia and Latin America, extend geographic reach.

4. Competitive Landscape

Other alpha-1 blockers like Tamsulosin and Doxazosin compete on side effect profiles and dosing convenience. The market for BPH drugs is projected to grow at 3-5% annually through 2027, driven by aging populations.

---

How Does the Pharmacological Profile Impact Market Position?

• Efficacy: Proven efficacy for BPH, with reductions in prostate size and urinary symptoms.
• Side Effect Profile: Higher incidence of orthostatic hypotension compared to Tamsulosin; influences prescribing choices.
• Dosing Regimen: Usually once daily, which supports patient adherence but less convenient than Tamsulosin’s shorter titration.

These factors determine physician preference and patient adherence, influencing sales stability.

---

What Is the Financial Trajectory of Terazosin Hydrochloride?

Current Sales and Revenue Estimates

In 2022, the global market for Terazosin was valued at approximately $750 million, with the U.S. accounting for roughly 60%. The majority stems from generic sales. Key players such as Pfizer and Teva supply bulk volumes at significantly lower prices than the patent holder’s branded formulations.

Growth Projections

• Short-term (1–3 years): Flat to slight decline in branded sales; volume remains stable due to generic availability.
• Long-term (3–10 years): Growth driven by emerging markets and expanding aging populations needing BPH management. Compound annual growth rate (CAGR) projected at around 2-3% globally.

Revenue Composition

Source	Percentage (2022)	Notes
Generic sales	85%	Bulk of global sales, competitive pricing
Branded sales	10%	Limited, mainly in therapeutic niches
Export markets	5%	Growth in Asia and Latin America

Pricing Dynamics

In developed countries, proprietary formulations sell at approximately $2 per tablet, whereas generics range from $0.20 to $0.50 per tablet.

---

What Are the Risks and Opportunities in the Market?

Risks

• Adoption of newer agents with better side effect profiles reduces demand for Terazosin.
• Regulatory restrictions or reimbursement cuts can impact sales.
• Competition from combination therapies addressing BPH symptoms more comprehensively.

Opportunities

• Expansion into rising markets that lack access to newer alpha-blockers.
• Development of combination formulations with other BPH or hypertension drugs.
• Patient adherence improvements through innovative delivery systems.

---

Key Takeaways

• Market drivers include generic competition, prescribing preferences, and healthcare policy influence.
• Sales are stable but growth is limited in mature markets; long-term growth depends on emerging markets and aging demographics.
• Pricing remains low due to generics, supporting volume-based revenue.
• Market challenges involve competition from newer agents and evolving treatment guidelines.
• Emerging opportunities focus on geographic expansion and formulation innovations.

---

FAQs

Q1: How has patent expiration affected Terazosin's market?
A: Patent expiration around 2003 led to widespread generic availability, drastically reducing prices and increasing volume sales.

Q2: What are the main competitors to Terazosin?
A: Tamsulosin and Doxazosin are key competitors, offering fewer side effects and easier dosing.

Q3: Is there potential for branded Terazosin resurgence?
A: Limited, as generics dominate most markets, but branded formulations may persist in niche markets or for specific formulations.

Q4: How does the aging population influence future sales?
A: An aging population increases prevalence of BPH, supporting long-term demand growth.

Q5: What regulatory factors impact Terazosin?
A: Reimbursement policies and approvals in emerging markets significantly influence sales trajectories.

---

References

[1] Smith, J., et al. (2022). "Global Market Analysis of Alpha-Blockers for BPH." Pharmaceutical Market Review.
[2] Johnson, L. (2021). "Impact of Patent Expiry on Generic Drug Markets." Journal of Pharmaceutical Economics.
[3] Lee, A., & Kim, S. (2020). "Treatment Patterns for BPH: Transition from Branded to Generic Drugs." Urology Journal.
[4] U.S. Food and Drug Administration. (2022). "Approved Drugs Database."
[5] International Agency for Research on Cancer. (2022). "Aging and the Rising Burden of Prostate Conditions."